cm. There was no lesion of the extremities. The serum Na+ was 140 mmol/L, K' was 6.0 mmol/L, creatinine was 460 ,umol/L, urea nitrogen was 30 mmol/L, glucose was 102.1 mmol/L, and osmolality was 432 mmol/kg. Anti-islet cell antibodies were negative. Analysis of arterial blood gases revealed a pH of 7.11, HCO3 of 11 mmol/L, Paco2 of 34 mm Hg, and base excess of -17 mmol/L. A test for ketones was positive in a 1/64 dilution of serum.
mostly remained in bed since going home. On examination, the patient had a temperature of 98°F, heart rate of 120 beats per minute, and blood pressure of 130/90 mm Hg. He was tachypneic, but the chest was clear to auscultation. His left leg was swollen, warm, red, and slightly tender. The left thigh was 5 cm greater in circumference than the right. The patient was readmitted to hospital with a clinical diagnosis of deep venous thrombosis. Anticoagulation with heparin was begun. A chest radiograph was negative. Ventilation-perfusion scanning of the lungs showed a high probability of pulmonary embolus.
On the third morning after admission, the patient became acutely dyspneic and diaphoretic. Examination showed that his heart rate was 150 beats per minute, blood pressure 93/57 mm Hg, and respiratory rate 32 breaths per minute. The chest was clear to auscultation. Cardiac P2 was loud. Arterial blood gases on 100% 02 by face mask were Paco2, 33 mm Hg and Po2, 48 mm Hg. Partial thromboplastin time was 32.9 seconds (normal, 25 to 35 seconds). A bolus of 5000 U heparin was given IV. He was taken immediately to the intensive care unit, where he received 100 mg tissue plasminogen activator (TPA) intravenously. About 10 minutes later, his dyspnea was improved, blood pressure had risen to 120/70, and oxygen saturation had increased from 85% to 98%.
The remainder of his hospital course was uneventful, except for development of partial occlusion of the left radial artery at the site of arterial punctures. Doppler imaging of the venous flow in the lower extremities showed thrombus in the left femoral and popliteal veins. After establishment of therapeutic anticoagulation with warfarin, he was discharged on March 22. Since that time, he has gained about 11 kg. Despite the weight gain, his glycemia has gradually improved, and insulin was discontinued in June. In July, glycosylated hemoglobin was 4.3% (normal, 4.0 to 6.0). In September 1993, 1 hour after 100 g oral glucose, serum glucose was 13.6 mmol/L, and C-peptide was 940 pmol/L (normal, about 1200 to 2000 pmol/L).
Classification of Diabetes Victor R. Lavis, MD
This case highlights current issues about the classification of diabetes mellitus. Table 1 summarizes some pertinent epidemiological, clinical, and pathophysiological characteristics of the most prevalent forms of diabetes in the United States.
Over about the last 15 years, through a series of epidemiological, immunological, and molecular investigations, "type I" diabetes mellitus, or insulin-depen- This case serves as a reminder that patients with decompensated diabetes probably are at increased risk for development of thromboembolic events. In several large series of adult patients with diabetic ketoacidosis or nonketotic hyperosmolar hyperglycemia,10-17 deaths from thromboembolism and disseminated intravascular coagulation accounted for 20% to 50% of the total mortality, as summarized in Table 2 . From 3% to 30% of the deaths were related to venous thrombosis. These numbers, which do not take into account the nonfatal and undiagnosed events, clearly underestimate the risk of thromboembolic complications.
The factors that interact to promote intravascular thromboses in patients with decompensated diabetes 21 The platelet abnormalities may have greater roles in arterial thrombosis and atherogenesis than in development of venous thrombosis. Hyperfibrinogenemia has also been reported, especially in patients with NIDDM, as reviewed in Reference 22 . In these patients, elevated fibrinogen levels may be more closely related to obesity or atherosclerosis than to diabetes per se. Other clinical investigations have shown evidence for diminished fibrinolysis (reviewed in References 20 and 23 through 25). Elevated plasma levels of plasminogen activator inhibitor 1 (PAI-i) have been described in patients with NIDDM but not those with type I diabetes (reviewed in Reference 24). Since PAI-1 levels correlate with degree of obesity as well as plasma levels of insulin and triglycerides,25 it appears that circulating PAI-1 is related primarily to insulin resistance rather than to the diabetic state per se. Circulating PAI-1 appears to be a marker for risk of arterial thrombosis; its role in venous thromboembolism is not yet known.
Elevation of circulating levels of von Willebrand factor has been reported especially in those diabetic patients with nephropathy or retinopathy,2627 suggesting a relation to endothelial dysfunction. In one series, increased levels of von Willebrand factor were associated with decompensated diabetes.28 Some investigators29 have reported reductions of circulating von Willebrand factor levels concomitant with institution of improved glycemic control, implicating a direct role for metabolic dysfunction, but others have found no such relation.
In general, the thrombogenic abnormalities have been reported to be more prevalent and more severe in patients who have microvascular disease (retinopathy, albuminuria) or symptomatic atherosclerosis than in those who have uncomplicated hyperglycemia. Perhaps hypercoagulability predisposes to diabetic angiopathy. Alternatively, atherosclerosis, microangiopathy, nephrop-athy, and coagulopathy may all reflect a more fundamental underlying disorder of endothelial function.
Further investigations in this area will be aided by development of sensitive and reliable tests that will reflect the activities of platelets and the coagulation and fibrinolytic pathways in vivo.
Thrombolytic Therapy for Pulmonary Thromboembolism Steven D. Brown, MD Hemodynamic compromise after pulmonary thromboembolism is directly proportional to the reduction in the cross-sectional area of the pulmonary capillary bed by the embolus or the subsequent vasoconstriction. Although hypoxemia commonly occurs after pulmonary thromboembolism, acute morbidity and mortality are often related to acute pulmonary hypertension, subsequent right ventricular failure, and a fall in cardiac output.
Three thrombolytic agents have been investigated for their ability to reverse hemodynamic compromise after pulmonary thromboembolism; streptokinase, urokinase, and TPA. All three activate the inactive proenzyme plasminogen, which circulates either free in plasma or noncovalently bound to fibrinogen and fibrin, converting plasminogen to plasmin. Despite its name, streptokinase is not an enzyme. Streptokinase binds and activates plasminogen, and the resultant streptokinaseplasmin complex activates adjacent plasminogen but does not degrade fibrin. Antibodies against streptokinase, a bacterial protein, are common and may lead to allergic reactions or to rapid binding of streptokinase and decreased thrombolytic efficacy. Urokinase, a naturally occurring human protein, activates free and fibrin-bound plasminogen directly. Unlike streptokinase and urokinase, TPA, also a naturally occurring protein, is relatively more specific for the activation of fibrinbound plasminogen. This property, however, has yet to translate into clinical advantage. Free urokinase and TPA have half-lives of a few minutes, because they are quickly bound to inhibitors. Ideally, plasmin should cleave only cross-linked fibrin. Unfortunately, plasmin also cleaves fibrinogen, and systemic degradation of the coagulation system with a risk of hemorrhage occurs at currently recommended doses of all thrombolytic agents.
An early report described the possible advantages of thrombolytic therapy over conventional heparinization in a canine model of acute pulmonary thromboembolism and in four human cases. 30 Although the trial was uncontrolled, two patients who did not improve hemodynamically on heparin alone promptly improved after streptokinase. The report raised a number of issues that remain unresolved, including the identification of the appropriate patient, the optimal duration of infusion and laboratory evaluation of the thrombolytic agent, and the concern for hemorrhage after thrombolytic therapies.
The Urokinase Pulmonary Embolism Trial compared urokinase followed by heparin with heparin therapy alone.31 Urokinase infused over a period of 12 hours produced more rapid improvement in pulmonary angiograms, perfusion scans, and right-sided hemodynamic measurements than heparin alone. Neither therapy resolved emboli completely. However, no difference was observed in mortality or the recurrence rate of pulmonary thromboembolism between the two groups at 2 weeks, whereas the incidence of hemorrhage was 45% in the urokinase group and 27% in the heparin-only group. Hemorrhage was associated closely with the invasive procedures of the study. Younger patients with preexisting cardiopulmonary disease and a larger, more acute embolic load appeared to receive a greater benefit from urokinase. The subsequent Urokinase-Streptokinase Embolism Trial compared a 12-hour infusion of urokinase to a 24-hour infusion of streptokinase or urokinase (all followed by heparin) in the therapy of pulmonary thromboembolism.32 Clot resolution was equal in both urokinase groups and greater in the 24-hour urokinase group than in the streptokinase group. The difference in clot resolution between the urokinase and streptokinase groups was most pronounced in patients with massive embolism. Nonfatal allergic reactions occurred in 3 of 58 patients treated with streptokinase and 1 of 113 patients treated with urokinase.
Many studies have compared TPA with other agents as therapy for pulmonary thromboembolism. Although a 2-hour infusion of 100 mg of TPA lysed clot more rapidly than a 12-hour infusion of urokinase after 2 hours of therapy, the same authors subsequently demonstrated that a larger initial bolus of urokinase lysed clot as effectively as TPA.33,34 Nonfatal allergic reactions occurred commonly after urokinase but not after TPA. 34 Right ventricular dysfunction and perfusion scans improved more rapidly after TPA followed by heparin than with heparin alone in hemodynamically stable patients who had acute pulmonary thromboembolism. 35 In that study, pulmonary thromboembolism recurred in 5 of 55 patients treated with heparin only and in 0 of 46 patients treated with TPA.
Smaller doses of TPA infused over a shorter period of time, followed by heparin, may limit the expense and complications of thrombolytic therapy for pulmonary thromboembolism. In an uncontrolled study of massive pulmonary thromboembolism in 54 patients, 1 mg/kg TPA infused over 10 minutes improved lung perfusion scans at 48 hours and at 10 days and improved hemodynamics in 11 of 15 patients with shock.36 In a study of 58 patients with acute pulmonary thromboembolism, 0.6 mg/kg TPA infused over 2 minutes produced a larger improvement in perfusion scans at 24 hours than did heparin alone.37 However, no difference in perfusion scans between the two groups was observed 7 days after the initiation of therapy, and no recurrent embolism was observed in either group during the study period. Minor 
